source
- GSK agrees $1.3 billion deal with Hutchmed for early-stage KRAS-EGFR cancer candidateGSK will pay $110 million upfront to Hutchmed as part of a deal that could reach $1.295 billion, giving GSK worldwide rights to develop and commercialize a preclinical oncology asset. The asset, i…
- FDA alerts hospitals to purge cassette fault in Abiomed Impella controllersThe FDA issued an Early Alert after identifying a problem with the purge cassette recognition in Abiomed’s Automated Impella Controllers, which could cause prolonged delays in mechanical circulator…